Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX008 plus Irinotecan in Second-line Advanced Gastric Cancer
NCT04486651Phase 3Unknown
- Sponsor
- Taizhou Hanzhong Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing HX008 + Irinotecan with Placebo + Irinotecan (2 arms). Primary endpoints: Overall Survival at 36 months and Overall Survival in Participants With PD-L1 CPS>=1 at 36 months. Status: unknown.
02
Drugs
pucotenlimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04486651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486651.